Qsemble Capital Management LP Buys Shares of 30,208 Zoetis Inc. $ZTS

Qsemble Capital Management LP bought a new stake in Zoetis Inc. (NYSE:ZTS) in the 2nd quarter, Holdings Channel reports. The institutional investor bought 30,208 shares of the company’s stock, valued at approximately $2,171,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in ZTS. Prosperity Bancshares Inc acquired a new stake in shares of Zoetis during the 4th quarter worth approximately $25,000. Cassaday & Co Wealth Management LLC acquired a new position in Zoetis during the first quarter valued at approximately $28,000. Elyxium Wealth LLC acquired a new position in Zoetis during the fourth quarter valued at approximately $32,000. Root Financial Partners LLC lifted its stake in Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after purchasing an additional 103 shares during the last quarter. Finally, Wellington Grp LLC lifted its stake in Zoetis by 6,675.0% during the first quarter. Wellington Grp LLC now owns 271 shares of the company’s stock worth $32,000 after purchasing an additional 267 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on ZTS shares. William Blair reiterated a “market perform” rating on shares of Zoetis in a research note on Thursday, August 6th. Stifel Nicolaus dropped their price objective on Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a research report on Friday, June 26th. Piper Sandler reduced their price objective on Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a research note on Monday, August 10th. Wall Street Zen lowered Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, Citigroup decreased their target price on Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a research report on Tuesday. Eight research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $109.62.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $73.64 on Friday. Zoetis Inc. has a one year low of $71.45 and a one year high of $160.48. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The company has a market cap of $30.43 billion, a price-to-earnings ratio of 12.13, a PEG ratio of 1.31 and a beta of 0.74. The firm has a 50 day simple moving average of $76.30 and a 200 day simple moving average of $99.01.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company’s revenue was down .2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Research analysts predict that Zoetis Inc. will post 6.19 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.9%. Zoetis’s dividend payout ratio (DPR) is currently 34.93%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.